Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with or without BMS-986205 in Endometrial Cancer
NCT04106414Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2019
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of linrodostat in endometrial cancer (EC) and endometrial carcinosarcoma (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Response at 1 year. Started Sep 2019; status: active, not recruiting.
02
Drugs
linrodostat
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on NCT04106414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04106414.